The text covers financial information for Cigna Corporation for the three and nine months ended September 30, 2020, compared to the same periods in 2019, including revenues, expenses, net income, comprehensive income, balance sheets, changes in total equity, and cash flows. Notable figures include total revenues of $40,955 million for the third quarter of 2020, net income of $1,398 million for the same period, and total assets of $160,044 million as of September 30, 2020. The company's financial statements also reflect operating activities, investments, liabilities, equity, and other financial transactions. In addition, the text delves into Cigna's investments, focusing on debt securities, equity securities, and commercial mortgage loans, detailing how these investments are classified, valued, and accounted for in financial statements. It discusses the adoption of ASU 2016-13 and changes in accounting policies regarding debt securities and commercial mortgage loans, impairments, credit loss allowances, credit quality evaluations, non-performance risks, retrocessional coverage, and fair value measurements as of September 30, 2020 and December 31, 2019.
The Management's Discussion and Analysis of Financial Condition and Results of Operations in the text provide detailed information about Cigna's financial status and performance, comparing it to previous periods. It delves into liquidity, critical accounting estimates, segment reporting, such as Evernorth and U.S. Medical, and adjustments to financial measures due to the impacts of the COVID-19 pandemic. The report also includes forward-looking statements and financial highlights by segment for specific periods. The COVID-19 pandemic significantly affected Cigna's operations, notably in the U.S. Medical segment, leading to deferred care by customers, increased medical utilization costs, and changes in investment income. Actions were taken to enhance liquidity, manage the pandemic response, and assess potential financial impacts. Regulatory actions related to the pandemic in the health insurance industry are discussed, along with implications for businesses like Cigna. The text also covers Medicare Advantage plans, ACA regulations, risk mitigation programs, liquidity, capital resources, financial activities like share repurchases and debt repayment, and strategies for managing capital resources and maintaining liquidity, as well as details on outstanding debt and long-term obligations.
The text discusses the disclosure of quantitative and qualitative information about market risk in a financial report. The information on market risk is provided under the section "Market Risk" in the Management's Discussion and Analysis of Financial Condition and Results of Operations, which is incorporated by reference in the report.
The text explains that Cigna's Chief Executive Officer and Chief Financial Officer conducted an evaluation of the effectiveness of the company's disclosure controls and procedures. They concluded that these controls and procedures are effective in ensuring that required information is properly disclosed within specified time periods. Additionally, there have been no significant changes in Cigna's internal control over financial reporting during the period covered by the report.
The text provided pertains to legal proceedings and incorporation of information from "Litigation Matters" and "Regulatory Matters" in Note 18 to the Consolidated Financial Statements.
The text refers to the risk factors that could impact a company's financial performance, as discussed in their Annual Report on Form 10-K for the year ended December 31, 2019, and supplemented by information in Form 10-Q for the quarter ended March 31, 2020. It states that there have been no significant changes to the previously reported risk factors.
Cigna's table provides data on its share repurchase activity for the quarter ended September 30, 2020, including the number of shares purchased, the average price paid per share, and the total dollar value of shares yet to be purchased. The company also allows employee shares tendered under equity compensation plans. Additionally, the company has a share repurchase program authorized by the Board of Directors, allowing repurchases depending on market conditions and alternate use of capital. The program may involve various methods like Rule 10b5-1 plans, open market purchases, or privately negotiated transactions. As of November 4, 2020, the company repurchased 2.8 million shares for approximately $500 million, with $3.1 billion in remaining repurchase authority.
I am ready to provide a summary of the text. Please go ahead and send the text parts for me to summarize.
I understand that you will be sending me multiple parts of text before I summarize it. Please go ahead and provide the text parts for me to summarize once you have sent them all.
I'm ready to help with summarizing the text once you provide it.
The text provided is an excerpt from a filing that includes various certifications and financial statements of Cigna Corporation in accordance with the Securities Exchange Act of 1934. It lists certifications from the Chief Executive Officer and Chief Financial Officer under relevant rules and includes financial statements from the quarterly report on Form 10-Q for the quarter ended September 30, 2020, formatted in XBRL. The filing also involves an interactive data file and concludes with a signature from Eric P. Palmer, the Executive Vice President and Chief Financial Officer of Cigna Corporation.
